AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15378476 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 3
Study 15378476 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 3
Study 15378476 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 3
Study 15378476 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 3
Study 15378476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 11790868 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily) for 3 weeks
Number of subjects: 0
Study 11790868 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily) for 1 week
Number of subjects: 0
Study 9508044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic fields (900 MHz, pulsed with 217 Hz, average power density 0.02 mW/cm2)
Number of subjects: 0
Study 9508044 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0
Study 9508044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic fields
Number of subjects: 0
Study 10147334 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic photorefractive keratectomy excimer laser
Number of subjects: 100000
Study 10147334 — intervention group
Group type: EXPERIMENTAL
Intervention: Multizone treatments
Number of subjects: 100000
Study 10147334 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser for compound myopic astigmatism
Number of subjects: 100000
Study 10147334 — intervention group
Group type: EXPERIMENTAL
Intervention: General laser technology
Number of subjects: 100000
Study 27756854 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC‐063 (multilayer-release methylphenidate)
Number of subjects: 59
Study 27756854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31026505 — intervention group
Group type: COMPARATOR
Intervention: Silencing of circHIPK3 in ovarian cancer cells (A2780 and SKOV3) and normal ovarian epithelial cells (IOSE80) via siRNA.
Number of subjects: 36
Study 31026505 — intervention group
Group type: EXPERIMENTAL
Intervention: CircHIPK3 expression in ovarian cancer tissues.
Number of subjects: 36
Study 31026505 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of circRNA expression profiling using NGS.
Number of subjects: 36
Study 28471766 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV counselling and testing (HCT)
Number of subjects: 121130
Study 26742307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixujieyu recipe combined with Gong‐Tune
Number of subjects: 75
Study 26742307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixujieyu recipe combined with Jiao‐Tune
Number of subjects: 75
Study 26742307 — intervention group
Group type: COMPARATOR
Intervention: Lixujieyu recipe alone
Number of subjects: 75
Study 23475691 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 2 mg twice daily
Number of subjects: 197
Study 23475691 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 197
Study 23475691 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 15 mg twice daily
Number of subjects: 197
Study 23475691 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study 23475691 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA
Number of subjects: 197
Study 21349585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medical and psychological treatment (including antidepressants and health-visitor delivered non-directive counselling)
Number of subjects: 0
Study 21349585 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study 21349585 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-visitor delivered non-directive counselling
Number of subjects: 0
Study 18422981 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 52
Study 18422981 — intervention group
Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 52
Study 17063220 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of oral citalopram
Number of subjects: 8
Study 17063220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12932601 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 31
Study 12932601 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no atorvastatin)
Number of subjects: 31
Study 10834216 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitra bands
Number of subjects: 150
Study 10834216 — intervention group
Group type: COMPARATOR
Intervention: Dentaurum bands
Number of subjects: 150
Study 9403353 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurenizide
Number of subjects: 75
Study 9403353 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (Control)
Number of subjects: 75
Study 8403176 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg.kg‐1 i.v.
Number of subjects: 24
Study 8403176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3535397 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 13)
Number of subjects: 25
Study 3535397 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 25
Study 31143439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (treated)
Number of subjects: 208
Study 31143439 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study 26845191 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (two 5‐mg tablets daily on days 2‐19)
Number of subjects: 25
Study 26845191 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (pemetrexed 500 mg/m(2) every 3 weeks and cisplatin 75 mg/m(2) every 3 weeks)
Number of subjects: 25
Study 24115225 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers and clinical parameters
Number of subjects: 90
Study 24115225 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite test using TGFβ, HSP-70, at-risk alcohol use, and Child class B
Number of subjects: 90
Study 24115225 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood test for HVPG
Number of subjects: 90
Study 20231678 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (paclitaxel 225 mg/m(2) and carboplatin AUC 6) followed by surgery
Number of subjects: 354
Study 20231678 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 354
Study 19620483 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 946
Study 16438075 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous closure with 2/0 polyglactin sutures (Group-I)
Number of subjects: 152
Study 16438075 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous closure (Group-II)
Number of subjects: 152
Study 12608907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector-system
Number of subjects: 20
Study 12608907 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 20
Study 12608907 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasonic system
Number of subjects: 20
Study 10606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Optically guided grasping forceps
Number of subjects: 80
Study 10606996 — intervention group
Group type: COMPARATOR
Intervention: Standard bronchoscopy forceps
Number of subjects: 80
Study 8605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood folic acid and vitamin B12 levels in neural tube defect pregnancies
Number of subjects: 135
Study 8605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic review of all studies
Number of subjects: 135
Study 8605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 135
Study 1902154 — intervention group
Group type: EXPERIMENTAL
Intervention: PA catheters with protective sleeves (group 1)
Number of subjects: 102
Study 1902154 — intervention group
Group type: COMPARATOR
Intervention: PA catheters without protective sleeves (group 2)
Number of subjects: 102
Study 1902154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 102
Study 6820918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Culture Urokinase (TCUK)
Number of subjects: 101
Study 6820918 — intervention group
Group type: COMPARATOR
Intervention: Urinary Urokinase (UUK)
Number of subjects: 101
Study 6820918 — intervention group
Group type: EXPERIMENTAL
Intervention: TCUK and UUK (combined with anti-cancer agents)
Number of subjects: 101
Study 29909433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (100, 200, or 400 µg)
Number of subjects: 98
Study 29909433 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl citrate IV 50 µg
Number of subjects: 98
Study 27304975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol 150 mg
Number of subjects: 30
Study 27304975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol (all doses)
Number of subjects: 30
Study 27304975 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenin-25
Number of subjects: 30
Study 25028911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 425
Study 25028911 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted Lopinavir (LPV/r)
Number of subjects: 425
Study 21964975 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeTalk intervention (4-session motivational interviewing-based program)
Number of subjects: 0
Study 21964975 — intervention group
Group type: COMPARATOR
Intervention: Heart-healthy attention-control
Number of subjects: 0
Study 20032281 — intervention group
Group type: COMPARATOR
Intervention: Chronic exercise
Number of subjects: 0
Study 20032281 — intervention group
Group type: COMPARATOR
Intervention: Acute exercise
Number of subjects: 0
Study 20201245 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 43
Study 20201245 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine + Donepezil
Number of subjects: 43
Study 20201245 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 43
Study 15925864 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation
Number of subjects: 112
Study 15925864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic posturography on a seesaw platform
Number of subjects: 112
Study 15925864 — intervention group
Group type: COMPARATOR
Intervention: Static conditions
Number of subjects: 112
Study 15925864 — intervention group
Group type: COMPARATOR
Intervention: Dynamic eyes-closed conditions
Number of subjects: 112
Study 15925864 — intervention group
Group type: COMPARATOR
Intervention: Dynamic conditions (pitch and roll planes)
Number of subjects: 112
Study 15925864 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural oscillations
Number of subjects: 112
Study 12622859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (verum) used twice daily for 3 weeks
Number of subjects: 50
Study 12622859 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel used twice daily for 3 weeks
Number of subjects: 50
Study 10638906 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB with 7 ml of 1% lidocaine
Number of subjects: 10
Study 10638906 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10
Study 10638906 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine injected intramuscularly (control)
Number of subjects: 10
Study 8867248 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at 3 g/kg and higher
Number of subjects: 6
Study 8867248 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) at 15 g/kg
Number of subjects: 6
Study 8867248 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at 15 g/kg and salicylic acid (SA) at 15 g/kg
Number of subjects: 6
Study 8867248 — intervention group
Group type: COMPARATOR
Intervention: Commercial ibuprofen (50 g/kg)
Number of subjects: 6
Study 8867248 — intervention group
Group type: COMPARATOR
Intervention: Benzocain creams (100 g/kg)
Number of subjects: 6
Study 8867248 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 6
Study 1644013 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 20
Study 1644013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6373155 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg)
Number of subjects: 24
Study 6373155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg)
Number of subjects: 24
Study 6373155 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 30998528 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee intake (150 mL, 3 times per day until discharge)
Number of subjects: 115
Study 30998528 — intervention group
Group type: COMPARATOR
Intervention: Tea intake (150 mL, 3 times per day until discharge)
Number of subjects: 115
Study 30998528 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee intake
Number of subjects: 115
Study 30998528 — intervention group
Group type: COMPARATOR
Intervention: Tea intake
Number of subjects: 115
Study 28340147 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 114
Study 28340147 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 114
Study 28340147 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle sensation
Number of subjects: 114
Study 26728501 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (m-CIMT)
Number of subjects: 22
Study 26728501 — intervention group
Group type: COMPARATOR
Intervention: control group (conventional therapy)
Number of subjects: 22
Study 25117849 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 461
Study 25117849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol craving
Number of subjects: 461
Study 19386949 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Medicines Management (IMM) program
Number of subjects: 117
Study 19386949 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control)
Number of subjects: 117
Study 17243862 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6458
Study 16209958 — intervention group
Group type: EXPERIMENTAL
Intervention: Edifoligide (Corgentech Inc, South San Francisco, Calif)
Number of subjects: 3014
Study 16209958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3014
Study 10975216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10975216 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP 0.025 mg x kg(‐1).min(‐1)
Number of subjects: 8
Study 10975216 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP 0.05 mg x kg(‐1) x min(‐1)
Number of subjects: 8
Study 10975216 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ANP
Number of subjects: 8
Study 8956392 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 24
Study 8956392 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 24
Study 1414321 — intervention group
Group type: EXPERIMENTAL
Intervention: SCMC-Lys (mucoregulatory drug)
Number of subjects: 40
Study 1414321 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 40
Study 2865251 — intervention group
Group type: EXPERIMENTAL
Intervention: oral concentrate
Number of subjects: 159
Study 2865251 — intervention group
Group type: COMPARATOR
Intervention: intramuscular medication
Number of subjects: 159
Study 31660915 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated delivery of mass drug administration (MDA) for soil-transmitted helminths (STH) and mass dog rabies vaccination (MDRV)
Number of subjects: 24
Study 31660915 — intervention group
Group type: COMPARATOR
Intervention: MDA only (Arm B)
Number of subjects: 24
Study 31660915 — intervention group
Group type: COMPARATOR
Intervention: MDRV only (Arm C)
Number of subjects: 24
Study 31660915 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated delivery (Arm A)
Number of subjects: 24
Study 29672719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive users (n=110)
Number of subjects: 201
Study 29672719 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of hormonal contraceptives (n=66)
Number of subjects: 201
Study 26815932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 1255
Study 26815932 — intervention group
Group type: COMPARATOR
Intervention: Oral systemic antibiotics
Number of subjects: 1255
Study 26815932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1255
Study 23257663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (IVRI) 0.5 mg/0.05 ml
Number of subjects: 40
Study 23257663 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 40
Study 20303785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 3223
Study 20303785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN)
Number of subjects: 3223
Study 21132065 — intervention group
Group type: EXPERIMENTAL
Intervention: High personal mastery (control component)
Number of subjects: 73
Study 21132065 — intervention group
Group type: EXPERIMENTAL
Intervention: High fatalism scores
Number of subjects: 73
Study 16051446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (maximum dose 2.5mg po tid)
Number of subjects: 70
Study 16051446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16051446 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine and Placebo
Number of subjects: 70
Study 12506163 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 228
Study 12506163 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP‐B (cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin)
Number of subjects: 228
Study 12506163 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP‐B
Number of subjects: 228
Study 11002958 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching programme (early group)
Number of subjects: 117
Study 11002958 — intervention group
Group type: COMPARATOR
Intervention: Control group (late group)
Number of subjects: 117
Study 8809437 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (RA)
Number of subjects: 30
Study 8809437 — intervention group
Group type: COMPARATOR
Intervention: Control group (48 subjects aged 19 to 65 years)
Number of subjects: 30
Study 1468291 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐102 APST
Number of subjects: 13
Study 1468291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 13
Study 3898794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50
Study 3898794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30911301 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet released growth factor (APRGF) injection (1-2 cc)
Number of subjects: 10
Study 30232851 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus fire-needle stimulation and cupping (Famciclovir 0.25 g three times a day, Mecobalamin 0.5 g three times a day, plus fire-needle stimulation and cupping once a day for 7 days)
Number of subjects: 60
Study 30232851 — intervention group
Group type: COMPARATOR
Intervention: Medication (Famciclovir 0.25 g three times a day, Mecobalamin 0.5 g three times a day)
Number of subjects: 60
Study 27636931 — intervention group
Group type: EXPERIMENTAL
Intervention: Afobazole (30 mg/day)
Number of subjects: 150
Study 27636931 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (30 mg/day)
Number of subjects: 150
Study 24835324 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine stress myocardial perfusion scintigraphy (MPS)
Number of subjects: 339
Study 24835324 — intervention group
Group type: COMPARATOR
Intervention: Normal MPS findings
Number of subjects: 339
Study 23088391 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital pay-for-performance demonstration project
Number of subjects: 420211
Study 23088391 — intervention group
Group type: COMPARATOR
Intervention: Comparison hospitals (780 propensity-score-matched)
Number of subjects: 420211
Study 20064680 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of mixed nuts daily for 12 weeks
Number of subjects: 50
Study 20064680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nuts)
Number of subjects: 50
Study 17938984 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 329
Study 17938984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 17938984 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (after open-label treatment)
Number of subjects: 329
Study 17938984 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after open-label treatment)
Number of subjects: 329
Study 17938984 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (at study end)
Number of subjects: 329
Study 17938984 — intervention group
Group type: COMPARATOR
Intervention: Placebo (at study end)
Number of subjects: 329
Study 19425461 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy plus physical therapy
Number of subjects: 64
Study 19425461 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 64
Study 15040936 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant OprF-OprI vaccine (intramuscular injection)
Number of subjects: 0
Study 15040936 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant OprF-OprI vaccine (intranasal application)
Number of subjects: 0
Study 11315819 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat diet
Number of subjects: 136
Study 11315819 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat diet (more compliant 50%)
Number of subjects: 136
Study 11315819 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 136